A new report, “Reimbursement Pathways for Psychedelic Therapies Across Europe”—funded by Norrsken Mind and co-authored by Martin Gisby and Floris Wolswijk—dives deep into one of the most pressing questions in psychedelic policy today: how do we ensure equitable, timely access to novel psychedelic treatments?
The report examines how European healthcare systems currently fund innovative mental health treatments and identifies key barriers—including stringent HTA evidence requirements, high upfront costs, and infrastructure limitations—that could slow the adoption of psychedelic therapies. In a detailed analysis, the report outlines actionable recommendations such as early payer engagement, innovative pricing models, and targeted cost-effectiveness analyses to overcome these obstacles.
PAREA collaborated in shaping the report. In the “Critical Observations from Collaborators” section, we share our reflections on what psychedelic and mental health advocacy can learn from earlier public health campaigns—particularly the HIV/AIDS treatment movement. Just as clinical advocacy played a key role in expanding access then, we believe that bringing together informed researchers, practitioners, and patient groups—as PAREA aims to do—can be a powerful force in accelerating access in the psychedelic field today.
